Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Eco Animal Health Group Plc
ESG Rating
Published Sep 28 2023
5 min read

ESG Rating

28 September 2023

ECO Animal Health Group plc

(''ECO", the "Company" or the "ECO Group")

(AIM: EAH)

ESG Rating

 

ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that it has achieved an A-rating for its ESG activities from Integrum ESG, who provide independent ESG ratings to a large number of companies.

 

An 'A' rating is the highest score possible and higher than approximately 300 other companies ranked in the same sub-sector. The rating reflects the ECO ESG strategy and activities and metrics, which are focused especially on environmental and social, particularly ethnic and gender diversity, aspects.

 

David Hallas, CEO commented: "ECO is committed to embedding sustainability into the high standards set for its business dealings. We recognise the value of incorporating the principles of Environment, Social and Governance (ESG) into everything we do and aspire to contribute to six of the UN SDGs which are aligned with our current and future business and intentions."

 

 

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

 

020 8447 8899

 

 

IFC Advisory

Graham Herring

Zach Cohen

 

 

020 3934 6630

 

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

 

020 7496 3000

 

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

Carlo Spingardi

 

020 7597 5970

 

 

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.